Current eradication strategies of tuberculosis (TB) in goats resemble bovine TB eradication programs and mainly relay on single and comparative intradermal tuberculin tests (SITT and CITT). TB vaccination has been proposed as a cost-effective option in high prevalent herds or countries were economic compensation for slaughter positive animals is not affordable. However, TB vaccination compromises the efficiency of TB standard diagnostic tests. In this study, the performance of a new diagnostic platform, based on the P22 antigenic complex, was assessed for skin test (ST), Interferon gamma release assay (IGRA) and serology under different TB scenarios. The sensitivity (Se) of diagnostic tests was assessed in TB infected goats from the same farm (herd A, N=77) and the specificity (Sp) was assessed in two TB negative farms, one TB unvaccinated (herd B, N=77) and another vaccinated with BCG (herd C, N= 68). The single (s) P22-IGRA showed the highest Se among IGRA tests (91%) and the comparative (c) P22-ST showed the highest Sp (100% in Herd B and 98% in Herd C). Combined interpretation of techniques enabled the best diagnostic performances. Combining the CITT + sP22-IGRA improved Se (97%) compared to CITT + tuberculin-based-IGRA (95%), with a reduction of Sp (95% and 100%, respectively). In addition, combination of P22-ELISA + cP22-ST or CITT elicited similar performance in the non-vaccination context (Se: 94% and 95%; Sp: 95% and 95%, respectively) but Sp was significantly higher in the combination with cP22-ST compared to CITT in vaccination context (95% and 79%, respectively). The combination of serological tests based on P22 and MPB83 showed higher complementarity and improved 13% the Se of P22-ELISA alone. These findings suggest that either cell-mediated or antibodies based diagnostic techniques, using the P22 antigen complex, can contribute to improve the immunodiagnostic of TB in goats under different TB control strategies.
Vaccination of goats against tuberculosis (TB) has been promoted as an ancillary tool for controlling the disease in infected livestock herds. A three-year trial to assess the efficacy of BCG vaccine was carried out in five goat herds. At the beginning of the trial (month 0), all animals were tested for TB using thee different diagnostic tests. Animals negative to all tests were vaccinated with BCG and all replacement goat kids were also systematically vaccinated throughout the trial. All animals were tested by Interferon-gamma release assay (IGRA) using vaccine compatible reagents at months 6, 12, 24, and 36. The risk factors for TB infection were also evaluated. At the end of the study, four out of five farms showed variable reductions of the initial prevalence (93.5%, 28.5%, 23.2%, and 14.3% respectively), and an overall incidence reduction of 50% was observed in BCG vaccinated goats, although adult vaccinated goats showed higher incidences than vaccinated goat kids. The unvaccinated positive animals remaining in herds and adult BCG vaccinated goats significantly enhanced the risk of infection in vaccinated animals. A systematic vaccination of goats with BCG, together with the removal of positive unvaccinated animals, may contribute to reducing the TB prevalence in goat herds.
Vaccination has been proposed as a supplementary tool for the control of tuberculosis in livestock. The long-term immunogenicity elicited by bacillus Calmette–Guerin (BCG) and the efficacy of revaccination were investigated in thirty goat kids distributed into three groups: unvaccinated controls, BCG (vaccinated at week 0) and BCG-BCG (vaccinated at weeks 0 and 56). Sixty-four weeks after the first vaccination, all animals were challenged with Mycobacterium caprae and examined post-mortem (pathology and bacterial load) at week 73. Antigen-specific interferon-gamma (IFN-γ) release was measured throughout the experiment. At week 59, peripheral blood mononuclear cells were stained for CD4, CD45RO and IFN-γ to determine the presence of antigen-specific cells secreting IFN-γ. The BCG-BCG group showed reductions in rectal temperatures, M. caprae DNA load in pulmonary lymph nodes (LN), the volume of lesions in pulmonary LN, mineralization in lungs, and higher weight gains compared to unvaccinated controls. IFN-γ responses were undetectable from 32 weeks after primary vaccination until revaccination, when the BCG-BCG group showed detectable IFN-γ production and a greater percentage of antigen-specific CD4+CD45RO+IFNγ+ and CD4−CD45RO+IFNγ+ cells compared to the BCG and control groups, which may be an indicator of the mechanisms of protection. Thus, re-vaccination of goats with BCG appears to prolong protection against infection with M. caprae.
Voles are maintenance hosts of Mycobacterium microti. In line with the goal to eradicate tuberculosis (TB) in livestock, the role of this mycobacteria needs to be assessed since it might interfere with current M. bovis/M. caprae surveillance strategies. To better understand the pathogenesis of TB in voles, an experimental infection model was set up to reproduce M. microti infection in laboratory Bank voles (Myodes glareolus). Two infection routes (intragastric and intraperitoneal) and doses (105 and 106 CFU/0.1 mL) were assessed. Voles were culled at different post-infection time points. Serology, histopathology, acid-fast bacilli staining, qPCR, and mycobacterial culture from tissues were performed. In addition, qPCR from feces and oral swabs were conducted to assess bacterial shedding. The model allowed us to faithfully reproduce the disease phenotype described in free-ranging voles and characterize the pathogenesis of the infection. Most animals showed multifocal and diffuse granulomatous lesions in the liver and spleen, respectively. Less frequently, granulomas were observed in lungs, lymph nodes, muscles, and salivary gland. Mycobacterial DNA was detected in feces from a few animals but not in oral swabs. However, one contact uninfected vole seroconverted and showed incipient TB compatible lesions, suggesting horizontal transmission between voles.